HOT OFF THE WIRE

Breaking News

Economy in U.S. Grew 4% in Second Quarter vs. 3% Estimate
Tweet TWEET

JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring Products for People with Type 1 Diabetes

JDRF Extends Collaboration with BD to Develop Combined Infusion and Monitoring
                   Products for People with Type 1 Diabetes

Combination of BD's proprietary technologies represents critical step toward
artificial pancreas

PR Newswire

FRANKLIN LAKES, N.J. and NEW YORK, June 18, 2013

FRANKLIN LAKES, N.J. and NEW YORK, June 18, 2013 /PRNewswire/ -- JDRF and BD
(Becton, Dickinson and Company) (NYSE:BDX) are accelerating the development of
new products that combine BD's proprietary insulin infusion and glucose
sensing technologies through a new collaboration announced today. This new,
three-year commitment is an extension of existing JDRF-BD collaborations
focused on type 1 diabetes (T1D).

Many patients with T1D not only take daily insulin via an insulin pump –
requiring a catheter to be placed in the body for a number of days – but are
also checking their glucose levels via a continuous glucose monitor (CGM),
which also requires a catheter-like sensor to be placed in the body for a
number of days.

While BD has been working to improve the products used for insulin infusion
and CGM, the new collaboration with JDRF will enable additional research to
develop a single optimized device that will perform both functions and
eliminate the need and complexities of multiple in-dwelling catheters. The
ability to perform these discrete metabolic actions automatically and
accurately, with little patient intervention, defines the artificial pancreas
concept.

"Providing the best tools that not only improve patient care, but ease the
daily burden of managing diabetes are important goals for BD and JDRF," said
Linda Tharby, President, BD Medical – Diabetes Care. "This latest
collaboration with JDRF demonstrates both parties' commitment to improve
patients' experiences and outcomes. Combining these novel technologies will
address two key components of an advanced artificial pancreas system."

"As the world's largest charitable funder of type 1 diabetes research, JDRF is
committed to advancing therapies that improve the lives of people living with
this disease," said Jeffrey Brewer, President and Chief Executive Officer of
JDRF. "We are excited to continue our collaboration with BD and support
efforts to develop novel technologies enabling advanced artificial pancreas
systems that will both measure glucose and administer insulin. Joining these
capabilities into a single solution will address significant patient needs and
help reduce the daily burden of managing type 1 diabetes."

T1D is an autoimmune disease in which the body's pancreas stops producing
insulin, a hormone needed to turn food into energy. BD's culture of innovation
and continuous improvement has enhanced the patient experience to help improve
therapy and outcomes for people with diabetes worldwide.BD devices support
earlier initiation and better adherence to prescribed therapies to help all
diabetes patients live healthier lives.

About BD
BD is a leading global medical technology company that develops, manufactures
and sells medical devices, instrument systems and reagents. The Company is
dedicated to improving people's health throughout the world. BD is focused on
improving drug delivery, enhancing the quality and speed of diagnosing
infectious diseases and cancers, and advancing research, discovery and
production of new drugs and vaccines. BD's capabilities are instrumental in
combating many of the world's most pressing diseases. Founded in 1897 and
headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000
associates in more than 50 countries throughout the world. The Company serves
healthcare institutions, life science researchers, clinical laboratories, the
pharmaceutical industry and the general public. For more information, please
visit www.bd.com.

About JDRF
JDRF is the leading global organization funding type 1 diabetes (T1D)
research. JDRF's goal is to progressively remove the impact of T1D from
people's lives until we achieve a world without T1D. JDRF collaborates with a
wide spectrum of partners and is the only organization with the scientific
resources, regulatory influence, and a working plan to better treat, prevent,
and eventually cure T1D.

As the largest charitable supporter of T1D research, JDRF is currently
sponsoring $530 million in scientific research in 17 countries. In 2012 alone,
JDRF provided more than $110 million to T1D research. More than 80 percent of
JDRF's expenditures directly support research and research-related education.
In 2012, Forbes magazine named JDRF one of its five All-Star charities, citing
the organization's efficiency and effectiveness. For more information, please
visitjdrf.org.

Contacts:
JDRF                           BD
Tara Wilcox-Ghanoonparvar      Lindsay Roman
(212) 479-7524                 (201) 847-4312
twilcox-ghanoonparvar@jdrf.org lindsay_roman@bd.com

SOURCE BD (Becton, Dickinson and Company); JDRF